Beyond TME : why do an exenteration?

Slides:



Advertisements
Similar presentations
Implementing NICE guidance
Advertisements

Neoadjuvant therapy for Rectal cancer
Oncologic Results of Laparoscopic Versus Conventional Open Surgery for Stage II or III Left-Sided Colon Cancers A Randomized Controlled Trial A randomized.
North Tees University Hospital Audit of T1 Rectal Cancers September 2013 – August 2014 Nicola Maguire Teaching fellow General Surgery 12/09/2014.
Multimodality Therapy of Rectal Cancer Robert D. Madoff, MD University of Minnesota.
T Staging: Rectal cancer T1 invades submucosa T2 invades muscularis propria T3 invades subserosa or perirectal tissues T4 invades peritoneum, organs or.
Amy Schindler 10/18/10.  Endoscopic appearance: Early cancers: superficial plaque, nodule, or ulceration Advanced lesions: strictures, ulcerated masses,
Role of colonoscopy in the treatment of malignant polyps Pathology of malignant colorectal polyps Assessing the risk of residual disease post-polypectomy.
JHSGR Neoadjuvant Therapy For Rectal Cancer Dr Chris TL Cheng Princess Margaret Hospital.
Pre-TME era. Mesorectal subsite/LN ALWAYS included in CTV Mesorectal subsite / LN region.
Colon Cancer Basic Science 9/21/05. Colon and rectal neoplasms are characterized by: Consist of the third most common site of new cancer cases and deaths.
Reporting and Management of Early stage Colorectal Cancer Frank Carey Dundee.
Management of early rectal carcinoma Joint Hospital Surgical Grand Round Jeren Lim United Christian Hospital.
Treatment of Early Malignant Rectal Polyp
Management of Locally Advanced Rectal Cancer Joint Hospital Surgical Grand Round Pamela Youde Nethersole Eastern Hospital Dr. YH Ling 19 May 2007.
THE SIGNIFICANCE OF HISTOLOGICAL SUBSTAGING IN CURATIVE RESECTED T3 COLORECTAL CANCER Karl Mrak & Jörg Tschmelitsch Department of Surgery, Barmherzige.
In the name of God Isfahan medical school Shahnaz Aram MD.
Rectal Cancer Alliance of Canada The webinar will begin shortly All participant lines will be muted during the presentation. Following the presentation,
Slides last updated: March 2015 CRC: STAGING. How colorectal cancer (CRC) is staged 1 Stage describes the extent of cancer, and is one of the most important.
Brendan Moran Basingstoke OCTOBER 2008
Oncological and functional outcome of ultra low colo – anal anastomosis with and without intersphincteric resection for low rectal cancer R.Ruppert Städt.
Current Role of Partial Cystectomy: Are we scarifying patient ’ s survival Dr Eric Li Department of Surgery Pamela Youde Nethersole hospital.
Preoperative chemoradiotherapy and postoperative chemotherapy with 5-FU and oxaliplatin versus 5-FU alone in locally advanced rectal cancer: First results.
* AP: Anteroposterior, Lat: Lateral Tumor diameter, tumor length, depth of penetration, distance from the anal verge, deep and narrow pelvic dimension.
Pelvic Anatomy from a Laparoscopic Perspective Tommaso Falcone MD Professor & Chairman Cleveland Clinic Foundation.
Local recurrence after rectal cancer resection is strongly related to the plane of surgical (PoS) dissection and is further reduced by pre-operative short.
T Staging: Rectal cancer T1 invades submucosa T2 invades muscularis propria T3 invades subserosa or perirectal tissues T4 invades peritoneum, organs or.
The management of recurrent pelvic malignancy
The Royal Marsden Solitary fibrous tumours The outcomes of 106 patients illustrating the unpredictable biological behaviour N Alexander, K Thway, JM Thomas,
Preliminary Results of the MRC CR07 / NCIC CO16 Randomized Trial Short course pre-op vs selective post-op chemo-RT for rectal cancer Local Recurrence after.
11:40-12:00 Mandating structured reports Eric Loveday.
Dr Mark Saunders Christie Hospital and Paterson Institute of Cancer Research “ Rectal cancer radiotherapy – why do we give it and how do we do it?”
Basingstoke Colorectal The Particular Problem of Low Rectal Cancer Brendan Moran Basingstoke 4 th East-West Colorectal Days Hungary 2008.
Role of MRI in Primary Rectal Cancer Staging and Management
Identification of localized rectal cancer (RC) patients (pts) who may NOT require preoperative (preop) chemoradiation (CRT). D. Roda 1, M. Frasson 2, E.
Rectal cancer staging go the full “DISTANCE” Geertje Noë.
Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer Anna Bill-Axelson, M.D., Lars Holmberg, M.D., Ph.D., Mirja Ruutu, M.D., Ph.D., Michael.
Carcinoma Vulva & Vagina
The Malignant Polyp Handout Version Hans Elzinga, MD Program Director- Advanced Procedures in Family Medicine Fellowship Salud Family Health Center-Longmont,
Staging of rectal cancer by EUS: depth of infiltration in T3 cancers is important Christian Jürgensen, MD, Andreas Teubner, MD, Jörg-Olaf Habeck, MD, Friederike.
Presented By Shin Fujita at 2016 ASCO Annual Meeting
Significance of Neoplastic Involvement of Margins Obtained by Endoscopic Mucosal Resection in Barrett’s Esophagus Ganapathy A. Prasad, M.D. Navtej S. Buttar,
Professor Guram Karazanashvili MD, KMSc, DMSc MMT Hospital.
The Perineum-II (Anal Triangle)
SPECC – Significant Polyp and Early Colorectal Cancer
Sigmoid and Colon cancer staging
Extramural venous invasion in rectal cancer
Karcinom rektuma- management
Gina Brown Academic Department of Radiology Royal Marsden Hospital, UK
Operative Approach and
Department of General Surgery, Upper Gastrointestinal Unit,
1 Maidstone and Tunbridge Wells NHS Trust (Kent Oncology Centre)
นายแพทย์ธราธร ตุงคะสมิต นายแพทย์ชำนาญการพิเศษ โรงพยาบาลมะเร็งอุดรธานี
New perioperative risk factors for biochemical recurrence after robotic assisted radical prostatectomy: A single surgeon experience in high volume Canadian.
SPECIMEN SONOGRAM - Procedure
MRI: techniques for rectal cancer staging and standardisation
Magnetic Resonance Imaging of Anorectal Neoplasms
Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer:
盧建璋, 陳鴻華, 李克釗, 胡萬祥, 張家駱, 蔡鎧隆, 林岳民, 鄭功全, 吳昆霖
Reporting Proformas for Colon and Rectal Cancer
Dr Jessica Jenkins Consultant Oncologist
Effect of Neoadjuvant Concurrent Chemoradiotherapy on Locally Advanced Middle and Low Rectal Cancer— A Propensity Score Matching Study 官泰全,林春吉,楊純豪,姜正愷,林宏鑫,藍苑慈,
The STAR-TREC Trial SIV Presentation
Detection and description of peritoneal metastases by CT
Changes in TNM 8 To be used from
Developments in Colorectal Cancer
Rashed Ghandour, Nirmish Singla, Yair Lotan  Trends in Cancer 
Classification of advanced rectal cancer
Presentation transcript:

Beyond TME : why do an exenteration? Gina Brown Department of Radiology Royal Marsden Hospital Imperial College, London

Beyond TME In a significant proportion of patients (15-20%), tumour extends beyond the achievable TME planes and requires more extensive surgery to achieve clear margins.

Exenterative surgery Radical resection can achieve complete tumor clearance. Reported R0 rates range from 22%-67%. Can significantly increase survival, enhancing the prospects for long term cure. High rate of post-operative adverse effects/morbidity. A.G. Heriot. Colorectal Dis,2006;8(9):733-747

Beyond TME Collaborative Trial : Multicentre open observational study To demonstrate that a validated staging system can be employed, Establish scale and scope of pelvic exenterative surgery in advanced rectal cancer beyond TME Assess quality of life and outcomes Develop prognostic classification to assist in counselling patients

Beyond TME trial Eligibility: Any rectal tumour extending beyond TME plane (primary or recurrent) Participating sites: Royal Marsden St Marks Oxford Southampton Swansea Edinburgh (tbc) Pls contact: Gina.brown@rmh.nhs.uk if you wish to recruit your patients to this study

Anatomic compartments beyond TME : the exenterative compartments Lateral Central Posterior Central Posterior Anterior Infra-levator

Reporting Proforma Advanced Tumour Requiring Surgery Beyond TME   Primary tumour The primary tumour is demonstrated as an [ Annular | Semi-annular | Ulcerating | | Polypoidal | Mucinous] mass with a [nodular / smooth] infiltrating border. The distal edge of the luminal tumour arises at a height of [ ] mm from anal verge: The distal edge of the tumour lies [ ]mm [Above,at, below] the top of the puborectalis sling The tumour extends craniocaudally over a distance of [ ] mm The proximal edge of tumour lies [above at below] the peritoneal reflection Invading edge of tumour extends from [ to ] O’clock Tumour is [confined to] [extends through] the muscularis propria: Extramural spread is [ ] mm mrT stage: [T1 ] [ T2 ] [ T3a] [ T3b ] [ T3c] [ T3d ] [T4visceral ] [T4 peritoneal]   Lymph node assessment Only benign reactive and no suspicious nodes shown [N0] [ ] mixed signal/irregular border nodes [N1/N2] Extramural venous invasion: [ No evidence ] [ Evidence] [ ] Small [ ]Medium [ ]Large vein invasion is present Peritoneal deposits: [ No evidence] [ Evidence] Pelvic side wall lymph nodes: [ None] [ Benign] [ Malignant mixed signal/irreg border] Location: [Obturator fossa • R •L ] . [External Iliac Nodes • R •L] .[internal iliac • R •L ]

Pelvic fascia are free of disease Laterally Pelvic fascia are free of disease Pelvic sidewall compartment are free of disease Internal/external iliac arterial /venous branches are free of disease Sacrotuberous/sacrospinous Piriformis/Obturator Infralevator compartment Levator muscles are free of disease Sphincter complex are free of disease Anterior urogenital triangle/Perineum Vaginal introitus/urethra : free of disease Retropubic space: : free of disease   Summary: MRI Overall stage: T N M , [ EMVI positive] [EMVI negative],[PSW positive ] [PSW negative], Total number of compartments, Closest potential surgical margins are located, Resection would require: Disease affects central compartment Above the peritoneal reflection within the pelvis Disease is present/ absent Ureters are free of disease   Below the Peritoneum anteriorly Bladder /Uterus/Vagina/Ovaries Prostate/Seminal vesicles/Urethra are free of disease Posteriorly The bony cortex/periosteum from S1-S2 is / is not involved by disease The bony cortex/periosteum from S3-S5 /coccyx is/ is not involved by disease Presacral fascia (S1/S2/S3/S4/S5) is not involved by disease Sciatic nerve/ S1/S2 nerve roots No disease Disease is present

MDT choices and making best use of high resolution MRI Local excision MINSTREL and STARTREC MRI T1/T2 Nx MRI based Selection of patients For range treatments MRI T3a/T3b N any Low rectal stage 1/2 Canadian “Quicksilver” and German “OCUM” trials MRI T3c/T3d N any EMVI positive CRM safe European RAPIDO trial, TRIGGER Chemoradiotherapy Restage – poor TRG Mercury II and BeyondTME trials potential CRM unsafe MRI advanced rectal cancer Post CRT yMRI TRG 1-2 TRIGGER Deferral of surgery

Reporting Minimum Standards

Reporting Template Post Treatment

Assessment of Rectal Cancer: how good quality MR imaging can help surgeons Is it malignant or not? What is the depth of invasion? Are lymph nodes involved? is there EMVI? Is the proposed excision plane safe? Early Rectal Cancers EMR/ESD: TEM Rectal Cancer Staging for primary TME vs preop CRT TME Low Rectal Cancer TME plane APE Beyond TME ELAPE Locally Advanced Rectal Cancer Beyond TME/Exenteration ESR/EMD/TEM: 5 slides TME – 5 slides TME plane APE and ELAPE: 5 slides Beyond TME - 5

>1mm submucosa free of tumour 1mm submucosa margin Local Excision Plane >1mm submucosa free of tumour 1mm submucosa margin Early Rectal Cancers

TEM plane >1mm muscularis free of tumour 1mm deep muscle margin

TME Mesorectal plane For coloanal anastomosis/ intersphincteric APE >1mm of intersphincteric plane clear

Beyond TME ELAPE plane <1mm intersphincteric plane clear

Beyond TME exenterative planes

Evidence base for MRI as a gold standard CRM involvement on MRI prognostic predictor for recurrence Depth of extramural spread >5mm risk factor for poor DFS Presence of MRI detected venous invasion – risk factor for local and distant recurrence and seen more frequently than path EMVI MRI detected mucinous tumours Tumour spread into or beyond the intersphincteric plane: risk of local recurrence MRI TRG status: independent prognostic predictor for overall survival and disease free survival and seen more frequently than the pathologic gold standard of pCR

Acknowledgements: Pelican Cancer Foundation European Mercury Study Group: Prof Bill Heald, Brendan Moran, Phil Quirke, I Swift, P Tekkis, S Stelzner, G Branagan, M Gudgeon, J Strassburg, S Laurberg, T Holm Radiologists in MERCURY I and II: Nicola Bees, Helena Blake, Rob Bleehan, Lennart Blomqvist, Alan Chalmers, Mike Creagh, Hanne-Linne Emblemsvaag, Sarah Evans, Ashley Guthrie, Chris George, Knut Håkon Hole, Nick Hughes, Shaun McGee, Petra Knuth, Delia Peppercorn, Clemens Schubert, Andrew Thrower, Turid Vertrus Research fellows: Sarah Burton, Neil Smith, Gisella Salerno, Fiona Taylor, Shwetal Dighe, Oliver Shihab, Peter How, Uday Patel, Jessica Evans, Chris Hunter, Panagiotis Georgiou, Vera Tudyka, Rafay Siddiqui, Jemma Bhoday, James Read, Manish Chand, Anita Wale, Alistair Slesser, Nick Battersby, Svetlana Balyasnikova , Anisha Patel and Mit Dattani 20

10th – 11th March 2016, London Intensive Hands On 2 Day Workshop Email: Gina.Brown@rmh.nhs.uk To receive further details 10th – 11th March 2016, London Intensive Hands On 2 Day Workshop How to perform Rectal MRI staging and restaging accurately and consistently HANDS ON Workstation PRACTICE Cases Case Discussions Tips and tricks for : Reporting and MDT based working